No published study has compared 0.5 ml of lip filler against 1 ml. Not for how the lips end up looking, and not for how often something goes wrong. When a clinic says half a syringe gives a subtle result and a full syringe gives an obvious one, that is a convention drawn from practice, not a finding from a trial.
A "half syringe" is not even a standard unit for most products. Only a few lip fillers are sold in a sub-1 ml size: Juvederm Ultra XC and Juvederm Volbella XC have an FDA-approved 0.55 ml fill, and Restylane and Restylane-L are supplied in 0.5 ml as well as 1 ml. For everything else, "0.5 ml" means the injector used part of a 1 ml syringe.
What is measured is that 1 ml does something visible. In a study of 36 women that injected a fixed 1 ml in every patient and measured the result with 3D photography, lip volume and projection were significantly greater than baseline at 4 weeks and at 12 weeks. That study randomised people by which product was used, not by how much — so it says nothing at all about 0.5 ml.
The counter-intuitive part is that the trials behind lip filler approval used far more than 1 ml. The Restylane lip trial injected a mean of 2.9 ml at initial treatment including touch-up, and the FDA-approved labeling for Juvederm Ultra XC describes roughly 2.2 ml as typical for the lips and perioral area at an initial treatment. "One syringe" is a commercial and practical unit. It is not a dose that came out of a study.
Juvederm Ultra XC and Volbella XC have an approved 0.55 ml fill; Restylane and Restylane-L come in 0.5 ml. Outside those, there is no half-size lip product.
1 ml is the default fill for Juvederm Ultra XC, Juvederm Volbella XC, Restylane, Restylane-L and Revanesse Lips+, which also comes in 1.2 ml.
No imaging or blinded-assessment study has used 0.5 ml as a study arm.
36 women, a fixed 1 ml in every patient, 3D photography: significant increase in lip volume and projection over baseline at 4 and 12 weeks. The randomisation was by crosslinking density, not by volume.
Juvederm Ultra XC's lip trial: 79.1% of treated people met a one-grade improvement at month 3, and 56.4% at month 12. Restylane Kysse: 60% at week 48. Restylane Silk: 58.8% at week 24. Separate products, separate trials, separate scales — the numbers are not comparable with each other.
There is no published data on what is done with it, or on whether storing and reusing it carries any infection risk. It is a fair question to ask.
The gap is real, and it runs in both directions. There is no dose-response research on filler volume at all, and the only lip study that looks like a volume comparison is not one. No randomised trial has compared 0.5 ml against 1 ml for either the aesthetic result or the complication rate.
The absence shows up from the other direction too. A 2019 systematic review of hyaluronic acid fillers for lip fullness pooled 22 studies and 3,965 people, nine of them randomised trials, and found responder rates across those studies ranging from 71% to 93.2%. The authors' own verdict on the field is the useful part: "The assessment methods (especially for efficacy) varied greatly from one study to another." That review identified no volume-comparison evidence.
So the half-versus-full framing is a practice convention. It may well be a sensible one. It has simply never been tested against the alternative, and nobody should present it as though it has been.
The lip is thinner than most people assume, and the target layer is thinner still. A cross-sectional ultrasound study of 126 people at clinics in London and Amsterdam found that the subcutaneous layer averaged less than 1 mm in both the upper and lower lip, so filler aimed at that layer ended up inside the muscle in most treated people. Vertical injection techniques were associated with deeper deposition, hypervascularity and evidence of migration. The study is observational, and several authors have commercial interests in ultrasound training, so it shows association rather than cause. It still reframes the question: where the product goes matters at least as much as how much of it there is.
The second input is the product. Restylane Silk has an FDA-documented gel particle size of 50 to 220 microns at the median, the smallest in the Restylane range. Juvederm Volbella XC contains 15 mg/ml of hyaluronic acid, the lowest concentration in the Juvederm range. Those are documented differences. But concentration is a poor guide to firmness — Restylane Lyft, Kysse, Refyne, Defyne, Contour and Eyelight are all 20 mg/ml and all behave differently.
There is also a measurement point worth knowing. In an independent laboratory comparison of several gels, Juvederm Volbella — the product marketed as the softest and most delicate — showed a higher elastic modulus than the other Allergan gels tested, roughly approaching the Restylane values. Marketing language about softness and measured firmness are not the same thing.
This matters more than the volume. In the US, the hyaluronic acid fillers with an FDA-approved lip augmentation indication are Juvederm Ultra XC, Juvederm Volbella XC, Restylane, Restylane-L, Restylane Silk, Restylane Kysse, Revanesse Lips+, RHA 3 and RHA 3 Mepi, and Belotero Intense (+) Lidocaine, which was approved in July 2026.
Several products people assume are lip fillers are not approved for lips: Juvederm Ultra Plus XC, Voluma XC, Vollure XC, Volux XC and Skinvive; Restylane Lyft, Refyne, Defyne, Contour and Eyelight. Using them in the lips is off-label, which is legal and happens routinely — but it means there is no trial in that area behind the choice.
The age wording is per manufacturer and worth quoting as written. Allergan and Galderma products say "in adults over the age of 21" or "in patients over the age of 21." Revanesse and RHA use "22 years of age or more."
No professional society currently publishes a per-syringe price: The American Society of Plastic Surgeons stopped reporting fees for minimally invasive procedures after its 2023 statistics report, whose last figure for lip augmentation was $698 - a per-procedure surgeon fee that counts a visit as one procedure however many syringes were used, so it cannot be read as a price for 1 ml.
Any change in vision, blurring or loss of vision, in one or both eyes
Sudden severe pain, or pain out of proportion to the procedure
Skin that turns white or pale, then dusky, grey, blotchy or net-patterned
Weakness, drooping, difficulty speaking or any other stroke-like symptom
These can indicate that filler has entered or blocked an artery. Time matters in hours, not days. Published guidance treats suspected blockage of an artery to the eye as a same-hour emergency; the most cited window is 90 minutes, and the American Society for Dermatologic Surgery notes that newer literature suggests it may be as little as 10 to 15 minutes. Do not wait to see whether it settles, and do not rely on pain as the signal — in a survey of experienced injectors who had had an intravascular injection, pain was mild or absent in 47% of those events.
Swelling is still increasing after the first few days rather than settling
A lump appears and does not settle, or appears weeks or months later
Redness spreads outward from the injection site, or you develop a fever
Tenderness or firmness comes on late, after a viral illness, a vaccination or dental work
The filler looks like it has moved outside the lip border
A cluster of small painful blisters appears, which can be a cold sore flare